Abstract
The crystal structure of 2-(3-ethoxy-4-(methoxycarbonyl)phenyl) acetic acid (RGA), an important intermediate in the preparation of Repaglinide, has been carried out. Hydrogen bonds between the carboxylate groups link the molecules into dimers while weak C–H···π interactions link these dimers into a one-dimensional chain lying along the crystallographic b axis. 4-(Carboxymethyl)-2-ethoxybenzoic acid (RGAA), an impurity observed in the preparation of Repaglinide, has been simply synthesized by the hydrolysis of RGA under basic conditions. Hydrogen bonds between the carboxylate groups link the molecules into dimers while weak C–H···O interactions connect these dimers into a one-dimensional chain lying along the crystallographic c axis. The compound RGAA has also been characterized by FT-IR and UV–Vis spectra, and by 1H NMR analysis. RGA: monoclinic, P21/n, a = 12.848(3) Å, b = 4.5539(10) Å, c = 22.328(5) Å, α = 90°, β = 101.703(5)°, γ = 90°, V = 1279.2(5) Å3. RGAA: monoclinic, P21/n, a = 14.0877(11) Å, b = 5.1814(3) Å, c = 14.5857(11) Å, α = 90°, β = 91.578(3)°, γ = 90°, V = 1064.26(13) Å3. The thermal behaviors and fluorescence properties of RGAA were also investigated.
Graphic Abstract
The crystal structures of one key intermediate of Repaglinide and its derivative have been characterized, where their luminescence properties and thermal behavior have been investigated.
Similar content being viewed by others
References
Culy CR, Jarvis B (2001) Drugs 61:1625–1660
Plosker GL, Figgitt DP (2004) Pharmacoeconomics 22:389–411
Scott LJ (2012) Drugs 72:249–272
Barbara JE, Kandel S, Stanley FA, Buckley DB (2014) Drug Metab Rev 45:179–180
Gertz M, Sall C, Houston JB, Galetin A (2014) Drug Metab Rev 45:258
Barbara JE, Muranjan S, Stanley F, Kollu C, Kandel S, Otwell C, Buckley DB (2015) Drug Metab Rev 47:120
Salman M, Babu SJ, Ray PC, Biswas S, Kumar N (2002) Org Process Res Dev 6:184–186
Grell W, Hurnaus R, Griss G, Mark RSERM, Luger P, Nar H, Wittneben H, Muller P (1998) J Med Chem 41:5219–5246
Panelo A, Wing JR (2005) Diabetes Care 28:1789
Wolffenbuttel BHR, Nijst L, Sels J, Menheere P, Muller PG, Kruseman ACN (1993) Eur J Clin Pharmacol 45:113–116
Sundaram DTSS, Mitra J, Rajesh C, Islam A, Prabahar KJ, Rao BV, Douglas SP (2015) Synth Commun 45:2092–2098
Zhang Y, Liu TT, Niu ZH, Fu YJ, Yang JX, Song YX, Zhao SC (2016) J Chem Res 11:506–510
Zhou XY, Zhu J, Bao ZJ, Shang ZH, Wang T, Song JF, Sun J, Li W, Adelusi TI, Wang Y, Lv DM, Lu Q, Yin XX (2016) Sci Rep 6:28023
Amin MM, Arbid MS (2017) Appl Physiol Nutr Metab 42:181–192
Awasthi R, Kulkarni GT, Ramana MV, Pinto TDA, Kikuchi IS, Ghisleni DD, Braga MD, De Bank P, Dua K (2017) Int J Biol Macromol 97:721–732
Kassem AA, Abd El-Alim SH, Basha M, Salama A (2017) Eur J Pharm Sci 99:75–84
Okunlola A, Adebayo AS, Adeyeye MC (2017) Int J Biol Macromol 94:544–553
Prior SL, Dunseath GJ, Luzio SD, Stephens JW (2017) Diabetic Med 34:65–66
Xu YT, Lu J, Zhou DD, Wang YD, Li JJ, Wang MY, Zhang HJ (2017) Drug Metab Pharmacok 32:S65–S66
Yamazaki T, Desai A, Goldwater R, Han D, Howieson C, Akhtar S, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Townsend R (2017) Clin Pharm Drug Dev 6:54–65
Sheldrick GM (1996, 2003) SADABS. University of Göttingen, Göttingen
Bruker AXS Inc. (1998) SAINT software reference manual. Bruker AXS Inc., Madison
Sheldrick GM (1997) SHELXTL NT version 5.1. Program for solution and refinement of crystal structures. University of Göttingen, Göttingen
Sheldrick GM (2008) Acta Crystallogr A 64:112–122
Accelrys (2014) Material studio release notes, release 7.0. Accelrys Software
Montazerozohori M, Mojahedi Jahromi S, Masoudiasl A, McArdle P (2015) Spectrochim Acta A 138:517–528
Wang P, Zhao L (2015) Spectrochim Acta A 135:342–350
Wang JH, Tang GM, Wang YT, Qin TX, Ng SW (2014) CrystEngComm 16:2660–2683
Wen YH, Dou RT, Yao K, Xu GF (2015) J Coord Chem 68:38–54
Chang XH, Zhao Y, Han ML, Ma LF, Wang LY (2014) CrystEngComm 16:6417–6424
Cheng L, Wang JQ, Gou SH (2011) Inorg Chem Commun 14:1201–1203
Wang CC, Wang JH, Tang GM, Wang YT, Cui YZ, Ng SW (2015) J Coord Chem 68:3918–3931
Tang G-M, Chi R-H, Wan W-Z, Chen Z-Q, Yan T-X, Dong Y-P, Wang Y-T, Cui Y-Z (2017) J Lumin 185:1–9
Acknowledgements
This work was financially supported by the Project of Shandong Province Higher Educational Science and Technology Program (J09LB03), Shandong Distinguished Middle-aged Young Scientist Encouragement and Reward Foundation (BS2011CL034), and Shandong Province Natural Scientific Foundation (ZR2017MB041). We thanks to one of reviewers giving a lot of good comments.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Appendix: Supplementary Material
Appendix: Supplementary Material
Crystallographic data for the structural analysis have been deposited with the Cambridge Crystallographic Data Centre, CCDC references numbers are 1500755 and 1500756 for compounds RGA and RGAA, respectively. Copies of this information may be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336 033; e-mail: deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk).
Rights and permissions
About this article
Cite this article
Tang, GM., Wang, YT. & Wu, YS. Preparation, Characterization and Crystal Structures of a Key Intermediate, and a Significant Impurity, in the Synthesis of Repaglinide. J Chem Crystallogr 50, 381–386 (2020). https://doi.org/10.1007/s10870-019-00811-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-019-00811-7